FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Utter Christine Marie				2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT]						ationship of Reportin k all applicable) Director Officer (give title	10% (
(Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 12/02/2024						below) below) below) VP, CHIEF ACCOUNTING OFFICER				
(Street) WARREN (City)	NJ (State)	07059 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table I - No	n-Derivative :	Securities Acc	uired	l, Dis	sposed of,	or Bei	neficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		action (Instr.	4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111501. 4)		
Common Stock	K		12/02/2024		M ⁽¹⁾		3,105	Α	\$51	55,533	D			
Common Stock	ς.		12/02/2024		S ⁽¹⁾		2,497	D	\$51.34(2)	53,036	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

S(1)

 $M^{(1)}$

 $S^{(1)}$

S⁽¹⁾

608

14,695

9,919

4,776

l			(5-,	,		-,		, - ,			,				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Execution Date,	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$51	12/02/2024		M ⁽¹⁾			3,105	(6)	01/02/2025	Common Stock	3,105	\$0	14,695	D	
Stock Option (Right to Buy)	\$51	12/02/2024		M ⁽¹⁾			14,695	(6)	01/02/2025	Common Stock	14,695	\$0	0	D	

Explanation of Responses:

Common Stock

Common Stock

Common Stock

Common Stock

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 27, 2024.

12/02/2024

12/02/2024

12/02/2024

12/02/2024

- 2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$51.15 to \$52.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$52.16 to \$52.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$51.15 to \$52.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$52.15 to \$52.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. Currently exercisable

/s/ Avraham S. Adler, Attorney-12/04/2024 in-Fact

\$52.24(3)

\$51

\$51.53(4)

\$52.45(5)

52,428

67,123

57,204

52,428

D

D

D

D

D

A

D

D

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.										